NT5E and triple-negative breast carcinoma: CD73 is expressed in a multitude of cancers and its significance in tumor progression is supported by studies showing that CD73 expression levels correlated with worse prognosis in triple-negative breast cancer as well as in gastric, colorectal, and gallbladder cancer (84–87).